Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
KS.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MM.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.48.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.4.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MC.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LP.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.50.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.43NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JC.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDPNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23154.8US
KP.3.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.3.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.2.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LU.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LF.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.28.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.6.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.61NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FR.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.2.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.33NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GP.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.7.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.1.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDYNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.18.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.4.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
ME.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LE.1.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDR.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.49.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HV.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used